FDA approves innovative T cell immunotherapy for rare soft-tissue cancer

Plus: What will become of the Cancer Moonshot?

August 2, 2024 Check out STAT+

Sponsored By

Wikimedia Commons STAT+ | FDA approves innovative T cell immunotherapy for rare soft-tissue cancer The medicine, called Tecelra, is a T cell receptor treatment, an emerging type of immunotherapy showing promise in solid tumors. By Andrew Joseph With Biden's departure in sight, advocates seek to preserve gains of Cancer Moonshot Advocates say Biden's Cancer Moonshot has brought "an unprecedented level of collaboration" and are mobilizing to preserve gains. By Angus Chen Opinion: Rising rates of skin cancer: The cost of FDA's inaction on novel sunscreen products First Opinion: Dermatologist sees better sunscreens in use overseas, blames red tape for FDA not approving a single new sunscreen ingredient this century. By Darrell Rigel Jacqueline Larma/AP Opinion: Address liquid biopsy disparities today to ensure equity in outcomes tomorrow Liquid biopsy, a tool to detect hidden cancer, is maturing at a rapid pace. Now is the time build a roadmap for its equitable use. By Gebra Cuyun Carter and Caitlin Kubler

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser